CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA’s second-half surge in approvals made 2008 the agency’s best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation.
You may also be interested in...
An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.